Zacks Research Issues Positive Outlook for COCP Earnings

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Stock analysts at Zacks Research upped their Q3 2026 EPS estimates for shares of Cocrystal Pharma in a research note issued on Thursday, August 20th. Zacks Research analyst D. Bautz now expects that the company will earn ($0.14) per share for the quarter, up from their previous forecast of ($0.19). The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($0.65) per share. Zacks Research also issued estimates for Cocrystal Pharma’s Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at ($0.58) EPS and FY2028 earnings at ($0.63) EPS.

Cocrystal Pharma (NASDAQ:COCP) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). The business had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.10 million.

Separately, Weiss Ratings lowered shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Cocrystal Pharma Trading Up 1.8%

Shares of COCP stock opened at $1.13 on Monday. Cocrystal Pharma has a 1 year low of $0.76 and a 1 year high of $2.67. The firm’s 50 day moving average is $1.01 and its 200-day moving average is $1.11. The firm has a market capitalization of $21.76 million, a price-to-earnings ratio of -1.49 and a beta of 1.43.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC acquired a new stake in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 6.72% of the company’s stock.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.